Insights

Gathering insights about Acumen…

Similar companies to Acumen

Acumen Tech Stack

Acumen uses 8 technology products and services including Facebook Pixel, Open Graph, Font Awesome, and more. Explore Acumen's tech stack below.

Facebook Pixel
Analytics
Open Graph
Content Management System
Font Awesome
Font Scripts
Swiper
Javascript Libraries
Elementor
Page Builders
PHP
Programming Languages
reCAPTCHA
Security
Nginx
Web Servers

Media & News

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease
Apr 02, 2025 | www.globenewswire.com
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast.
Mar 27, 2025 | seekingalpha.com
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Mar 20, 2025 | www.globenewswire.com
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease.
Mar 18, 2025 | www.globenewswire.com
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug
Mar 12, 2025 | www.globenewswire.com
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
Mar 10, 2025 | www.globenewswire.com
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
Nov 26, 2024 | www.globenewswire.com

Acumen's Email Address Formats

Acumen uses at least 1 format(s):

Acumen Email Formats	Example	Percentage
First.Last@acumen.be	John.Doe@acumen.be	82%
First.MiddleLast@acumen.be	John.MichaelDoe@acumen.be	7%
First@acumen.be	John@acumen.be	8%
First.Middle.Last@acumen.be	John.Michael.Doe@acumen.be	3%

Frequently Asked Questions

Where is Acumen's headquarters located?

Acumen's main headquarters is located at Ambachtenlaan 14 Heverlee, Flemish Region 3001 BE. The company has employees across 6 continents, including EuropeAsiaNorth America.

What is Acumen's stock symbol?

Acumen is a publicly traded company; the company's stock symbol is ABOS.

What is Acumen's official website and social media links?

Acumen's official website is acumen.be and has social profiles on LinkedIn.

How much revenue does Acumen generate?

As of January 2025, Acumen's annual revenue reached $3.8M.

What is Acumen's NAICS code?

Acumen's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Acumen have currently?

As of January 2025, Acumen has approximately 66 employees across 6 continents, including EuropeAsiaNorth America. Key team members include Data Analytics Consultant And Partner: B. V. W.Partner: B. W.President: J. A.. Explore Acumen's employee directory with LeadIQ.